RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.

被引：0
|
作者：
Zhang, Li
Yang, Yunpeng
Pan, Jian-Ji
Chen, Xiaozhong
Sun, Yan
Wang, Hui
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 36期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
    Wu, Xiaohua
    Sun, Yang
    Yang, Hongying
    Wang, Jing
    Lou, Hanmei
    Li, Dan
    Wang, Ke
    Zhang, Hui
    Wu, Tao
    Li, Yuzhi
    Wang, Chunyan
    Li, Guiling
    Wang, Yifeng
    Li, Dapeng
    Tang, Ying
    Pan, Mei
    Cai, Hongyi
    Wang, Weihu
    Yang, Bing
    Qian, Hua
    Tian, Qiuhong
    Yao, Desheng
    Cheng, Ying
    Wei, Bing
    Li, Xiumin
    Wang, Tao
    Hao, Min
    Wang, Xiaohong
    Wang, Tiejun
    Ran, Juntao
    Zhu, Hong
    Zhu, Lijing
    Liu, Xianling
    Li, Yunxia
    Chen, Lihong
    Li, Qingshan
    Yan, Xiaojian
    Wang, Fei
    Cai, Hongbing
    Zhang, Yunyan
    Liang, Zhiqing
    Liu, Funan
    Huang, Yi
    Xia, Bairong
    Qu, Pengpeng
    Zhu, Genhai
    Chen, Youguo
    Song, Kun
    Sun, Meili
    Chen, Zhengzheng
    LANCET, 2024, 404 (10463): : 1668 - 1676
  • [32] Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
    Shu, Yongqian
    Pan, Yueyin
    Lu, Ping
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Ba, Yi
    He, Zhiyong
    Bai, Yuxian
    Chen, Jianhua
    Yu, Guohua
    Peng, Yanyan
    Wu, Hongqian
    Wang, Lei
    Li, Liyun
    Xu, Jianming
    CANCER RESEARCH, 2023, 83 (08)
  • [33] Cisplatin and gemcitabine plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase 2 trial
    Valle, J. W.
    Bousmans, N.
    Zhang, W.
    Walgren, R. A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2016, 27 : vi240
  • [34] Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
    Lu, Zhihao
    Wang, Junye
    Shu, Yongqian
    Kong, Li
    Wang, Buhai
    Yang, Lei
    Cao, Guochun
    Sun, Guogui
    Ji, Yinghua
    Liu, Hu
    Cui, Tongjian
    Qiu, Wensheng
    Zaanan, Aziz
    Cid, Roberto Pazo
    Zhou, Hui
    Sun, Xing
    Wang, Yan
    Chen, Yuling
    Li, Haoyuan
    Zhang, Lishi
    Shen, Lin
    CANCER RESEARCH, 2023, 83 (08)
  • [35] A multicenter, randomized, double-blind, placebo-controlled phase Ill study of anlotinib or placebo in combination with gemcitabine and cisplatin (GP) as first -line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Ma, Yuxiang
    Cai, Qingqing
    Li, Zhi-Ming
    Zhao, Hongyun
    Zhao, Yuanyuan
    Zhou, Ting
    Hong, Shaodong
    Zhang, Yaxiong
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
    Mettu, Niharika B.
    Niedzwiecki, Donna
    Boland, Patrick Mckay
    Fakih, Marwan
    Arrowood, Christy
    Bolch, Emily
    Hurwitz, Herbert
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [37] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [38] Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.
    Sama, Ashwin Reddy
    Denlinger, Crystal Shereen
    Vogel, Arndt
    He, Aiwu Ruth
    Bousmans, Nathalie
    Zhang, Wei
    Walgren, Richard A.
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC)
    Miles, D. W.
    Chan, A.
    Romieu, G.
    Dirix, L.
    Cortes, J.
    Pivot, X.
    Tomczak, P.
    Juozaityte, E.
    Harbeck, N.
    Steger, G. G.
    CANCER RESEARCH, 2009, 69 (24) : 495S - 495S
  • [40] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Kim, Sung-Bae
    Dent, Rebecca
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven J.
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew J.
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    LANCET ONCOLOGY, 2017, 18 (10): : 1360 - 1372
12345